TORL-1-23 Generates Responses in Heavily Pretreated CLDN6-Positive Solid Tumors
Postsurgical Pembrolizumab/Chemotherapy Misses DFS Goal in Endometrial Cancer
Retifanlimab Plus Carboplatin and Paclitaxel Improve PFS in Recurrent/Metastatic Anal Cancer
Radium-223 Plus Enzalutamide Boosts Survival in mCRPC